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Background: Antibiotic resistance is a threat in developing countries (DCs) because of the high burden of bacterial
disease and the presence of risk factors for its emergence and spread. This threat is of particular concern for
neonates in DCs where over one-third of neonatal deaths may be attributable to severe infections and factors such
as malnutrition and HIV infection may increase the risk of death. Additional, undocumented deaths due to severe
infection may also occur due to the high frequency of at-home births in DCs.
Methods: We conducted a systematic review of studies published after 2000 on community-acquired invasive
bacterial infections and antibiotic resistance among neonates in DCs. Twenty-one articles met all inclusion criteria
and were included in the final analysis.
Results: Ninety percent of studies recruited participants at large or university hospitals. The majority of studies were
conducted in Sub-Saharan Africa (n = 10) and the Indian subcontinent (n = 8). Neonatal infection incidence ranged
from 2.9 (95% CI 1.9–4.2) to 24 (95% CI 21.8–25.7) for 1000 live births. The three most common bacterial isolates in
neonatal sepsis were Staphylococcus aureus, Escherichia coli, and Klebsiella. Information on antibiotic resistance was
sparse and often relied on few isolates. The majority of resistance studies were conducted prior to 2008. No
conclusions could be drawn on Enterobacteriaceae resistance to third generation cephalosporins or methicillin
resistance among Staphylococcus aureus.
Conclusions: Available data were found insufficient to draw a true, recent, and accurate picture of antibiotic
resistance in DCs among severe bacterial infection in neonates, particularly at the community level. Existing
neonatal sepsis treatment guidelines may no longer be appropriate, and these data are needed as the basis for
updated guidelines. Reliable microbiological and epidemiological data at the community level are needed in DCs
to combat the global challenge of antibiotic resistance especially among neonates among whom the burden is
greatest.
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Infectious disease remains the leading cause of death in
children under 5 in developing countries (DCs) with ne-
onates bearing the highest burden. In Africa alone, infec-
tious disease accounts for over 76% of under-5 deaths,
and an estimated 36% of neonatal deaths worldwide are
directly attributable to severe infections [1,2].
Moreover, DCs are also home to a number of risk fac-
tors for the emergence and spread of antibiotic resist-
ance. Misuse of antibiotics, over-the-counter and parallel
market access, and counterfeit or poor quality drugs,
combined with substandard hygiene and living condi-
tions, are the driving forces behind the emergence and
spread of antibiotic resistance [3,4]. The potential for the
development and rapid spread of new forms of resist-
ance is highlighted by the recent worldwide proliferation
of NDM-1-producing Enterobacteriaceae. The gene, which
confers resistance to carbapenems, originated in India in
2009, and since 2010 NDM-1-producing Enterobacteria-
ceae have been reported in North America, Europe, and
Asia [5]. The World Health Organization (WHO) has re-
cently heightened awareness of this pressing issue with
calls for action to contain antibiotic resistance on a global
scale [6].
A recent report estimates 6.9 million cases of possible
severe bacterial infection in neonates in sub-Saharan
Africa, south Asia, and Latin America in 2012 [7] under-
scoring the potential for excess morbidity and mortality
due to antibiotic resistance. In this context, antibiotic re-
sistance trends need to be monitored.
We report a systematic review examining studies deal-
ing with invasive bacterial infections and antibiotic re-
sistance among neonates in DCs with a special emphasis
placed on community-based studies.
Methods
An initial search was conducted for articles dealing with
infection and antibiotic resistance among children under
2. This search allowed us to identify both neonatal-
specific articles as well as articles dealing with young
childhood infection that included neonatal-specific
information.
We searched PubMed for studies published in 2000 or
later (last search April 30th, 2014). To overcome a
potential lack of studies dealing with both topics simul-
taneously, our search was divided into two branches in-
cluding 1) community-acquired bacterial infections in
infants of DCs (BI), and 2) antibiotic resistance among
community-acquired infections in DCs (AR). DCs were
identified as “least developed”, “other low income”, or
“lower middle income” by the World Bank or as “low
human development” or “medium human development”
by the United Nations [8,9]. We also screened reference
lists of relevant articles for further publications.Before paper selection, duplicates from the BI and AR
lists were eliminated. Detailed PubMed search and inclu-
sion criteria are shown Table 1. Abstracts were screened
for full text reading by two of the three reviewers (B-T.
H., M.P., and E.D.A.) and a third reviewer was called
upon as needed. Information was extracted from
selected articles including: study year, study location,
urban vs. rural location, hospital recruitment vs. other,
community or nosocomial infections, study design and
microbiology methods (bacterial isolation methods and
antibiotic susceptibility testing). Articles were then re-
evaluated by two reviewers as before.
Following the selection of articles for children <2,
those articles containing information on either bacterial
infection or resistance during the neonatal period were
retained for analysis. An effort was made to restrict the
selection to community-acquired infections, and all arti-
cles presenting exclusively nosocomial infections were
eliminated.
Results
Of the 1543 and 1314 studies returned from the BI and
AR searches, 84 and 46 were selected for full reading, re-
spectively (Figure 1). Ultimately, 20 BI studies and one
AR study were retained for a total of 21 studies included
in the final analysis. Of the 20 BI studies selected, 11
also met the selection criteria for inclusion in AR studies
and thus a total of 12 articles were included in the resist-
ance analyses.
A majority of studies came from Sub-Saharan Africa
(n = 10) or the Indian subcontinent (n = 8) (Table 2).
Design, recruitment settings, and study topics
Of the 21 articles analyzed, 17 used either a cross-
sectional or surveillance study design [10-26]. Four stud-
ies were conducted in rural settings [17,21,24,27] while
the remaining 17 were conducted in urban settings
(Table 2).
Nineteen of 21 studies recruited participants in large
district or university hospitals. Only two studies used
active community recruitment [27,28]. Sixteen of the 17
urban studies recruited uniquely at large hospitals.
Bacterial isolation rates
Thirteen of the 20 infant infection articles reported
bacteremia rates. Excluding one study from Georgia
with an isolation rate of 67% [14], isolation rates
ranged from 5.8% to 48% (median = 22.4%). No differ-
ence in rates was noted between urban and rural stud-
ies [11-15,18-21,23-27,29,30]. Only one study reported
bacterial isolation rates from cerebrospinal fluid cul-
tures, with a 4% positivity rate [24]. Of all BI articles,
two reported antibiotic use prior to blood culture, with
16% and 67% exposure rates, respectively [10,27] and
Table 1 Search strategy and selection criteria for neonatal infection and bacterial resistance articles in developing
countries (2000-May 2014)
Search strategy
For the BI search, each DC was cross-linked with search terms “Bacterial Infections” OR “Sepsis” OR “bacter*” AND “epidemiology”. For the AR
search, each DC was cross-linked with “Drug resistance, bacterial” OR (“antibiotic resistance” AND “bacter*”) AND “epidemiology”. Both searches
were restricted to English language articles and the BI search was restricted to the PubMed “infant” age category (birth-23 months). Both searches
were also limited by excluding the keywords and MeSH terms “travel”, “candida”, “HIV infection”, “leprosy”, “tuberculosis”, “tetanus”, “malaria”,
“cholera”, or “helicobacter”. The BI search was further limited by excluding the keywords “immunization”, “immunization program”, and
“vaccination”.
Inclusion criteria
Infant infection search (BI) Resistance search (AR)
● Information on bacterial infections including either etiology
or disease burden/incidence
● Bacterial pathogens
● Community acquired infections ● Community acquired infections
● Methodologically sound including clear inclusion criteria ● Information on antibiotic resistance profile of pathogen
(proportion resistance/susceptible, etc.)
● Sound microbiological methods/citation of guidelines used ● Sound microbiological methods/citation of guidelines used
● Neonatal specific information presented ● Information on pathogen source and/or clinical information
● Neonatal specific information presented
Exclusion criteria
Both branches
● Review study or expert opinion
● Outside of developing country list
● Purely nosocomial infections or no possibility to extract only community acquired infections from data
● Pathogen not in the restricted list, including Neisseria gonorrhoeae, Campylobacter, Helicobacter, Vibrio, Clostridium tetani, or any Mycobacteria
● Obvious methodological weakness including sampling methods
● Insufficient number of isolates/insufficient number of isolates for follow-up period (minimum 10 isolates per year)
● Data collection done principally before 2000
Infant infection search (BI) Resistance search (AR)
● Ages outside of range of interest or ages of interest
non-extractable
● Insufficient epidemiological info on sample source/patients/no. of
bacteria isolated from neonates
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[15,16].
Laboratory methods and antibiotic susceptibility testing
guidelines
Two of the 19 BI studies with blood cultures reported
taking two blood samples from patients [14,15]. Of
these 19 studies, 13 reported blood quantity taken
[10-13,15-19,21,23,25,27]. Overall, ten of 12 studies
retained in the AR analysis (see Figure 1) cited the use
of established guidelines for resistance interpretation
[11,12,19,20,24-26,28-30] with the majority referring
to the Clinical and Laboratory Standards Institute
(CSLSI) methods. Two studies cited external quality
control measures [24,27] and only Darmstadt et al.
[27] sent samples to a reference lab for confirmation.
Bacterial infection incidence estimates and pathogens
Of 20 studies of BI in neonates, five reported an incidence
rate for invasive bacterial infection (Figure 2) [18,23,27-29].Incidence rates per 1000 live births ranged from 2.9 (95%
CI 1.9–4.2) for bacteremia among neonates in Bangladesh
[27] to 24 (95% CI 21.8–25.7) for early onset sepsis
(<72 hours) in India [23]. Along with Darmstadt et al. [27],
Mir et al. [28] used community recruitment and reported
an incidence of 20.4 (95% CI 17.3–24.0) in Pakistan for
neonatal omphalitis with sepsis [28]. Studies based on hos-
pital recruitment reported sepsis incidence rates of 9.2
(95% CI 8.2–10.3) in Malawi [29] and 7.8 (95% CI 4.4–11.5)
in Nigeria [18] per 1000 live births. A third study using hos-
pital recruitment in India reported rates of 24 (95% CI
21.7–25.7) for early onset sepsis (<72 hours), and 16 (95%
CI 14.0–18.1) for late onset sepsis (>72 hours) [23].
Among the 20 neonatal studies reporting full bacterial
etiology, Staphylococcus aureus (S. aureus) was reported
in all but two, accounting for 3% to 63% (median =
32.5%) of pathogens. Other common pathogens included
Klebsiella spp., reported in 16 studies and ranging from
8% to 66% (median = 22%) of pathogens, and Escherichia
coli (E. coli), reported in 14 studies and ranging from 5%
Figure 1 Flowchart of literature search including both the infection incidence and antibiotic resistance branches. *Data was considered
not recent if data collection took place principally before 2000.
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et al. [23] reported that non-fermenting Gram-negative
bacteria were the most common isolates in early-onset
sepsis (first 72 hrs. of life) representing 30% of isolates,
followed by S. aureus (20%), Klebsiella pneumoniae (K.
pneumoniae) (12%), and E. coli (9%), whereas S. aureus
predominated in late-onset sepsis (31%), followed by non-
fermenting Gram-negative bacteria (17%), K. pneumoniae
(14%), and E. coli (11%) [23]. Blomberg et al. [10] and
Mhada et al. [11] reported results for early-onset sepsis
defined as 0–7 days. Both studies found early onset sepsis
was due primarily to Klebsiella spp. (33% and 32% re-
spectively), S. aureus (29%, 11%) and E. coli (19%, 11%)
with late-onset sepsis, defined as 7–28 days and 7–30 days
respectively, due mostly to S. aureus (55%, 16%), Klebsiella
spp. (23%, 23%), and E. coli (18%, 10%).
Twelve studies reported Group B streptococcus iso-
lates. Percentages were low overall, representing between
1% and 20% (median = 4.5) of blood culture isolates in
eleven studies [10,11,13-15,18,21,24,25,27-29].
Antibiotic resistance
The 12 studies with relevant antibiotic resistance infor-
mation for selected neonatal pathogens are presented
in Table 3. Seven of the 12 studies were conducted be-
fore 2008. Resistance to penicillin/ampicillin among
Gram-negative bacteria (not including Klebsiella spp.)
ranged from 55% (95% CI 26%-84%) among E. coliisolates in Georgia [14] to 100% among E. coli isolates
in Uganda [15]. Resistance to gentamicin among
Gram-negative bacteria ranged from 0% for Pseudo-
monas and E. coli in Pakistan [28] and for K. pneumo-
niae in Nepal [20] to 100% for K. pneumoniae in India
[25]. Among Gram-negative bacteria, resistance to
third generation cephalosporins (3rd GC) ranged from
6% for E. coli isolates in Uganda [15] to 97% among K.
pneumonia isolates in India [25]. Only two studies tested
for extended spectrum beta-lactamase (ESBL) production
in Enterobacteriaceae. One reported ESBL production in
87% of Klebsiella spp. isolates, 73% of Enterobacter spp.
isolates, and 65% of E. coli isolates [26]. The second found
32% ESBL production among K. pneumoniae isolates [25].
Resistance of S. aureus isolates to methicillin was reported
in five studies and ranged from 0% to 67% [14,19,24,28,30].
Discussion
Our results highlight the dramatic lack of data on bac-
terial resistance patterns in neonatal infections in de-
veloping countries. They also underscore the paucity
of reliable and convincing data on the burden of
community-acquired invasive bacterial infections in
newborns in these countries. This was pointed out by
Berkley et al. almost ten years ago and more recently
by Lubell et al. in 2009, demonstrating how little pro-
gress has been made on this issue [31,32]. These gaps in
knowledge impede the improvement of prevention and
Table 2 Neonatal infections in developing countries (2000-May 2014)
Author, country, and
study year
Disease type
and age
Setting Neonatal Isolation rate and aetiology*
Sub-Saharan Africa
Blomberg et al. [10] Bacteremia urban, hospital recruitment 54 early onset (EOS) isolates†: 31 late onset (LOS) isolates:
Tanzania 2001-2002 <7 yrs Klebsiella spp. EOS 14 (26%), LOS 7 (23%)
S. aureus EOS 6 (11%), LOS 5 (16%)
E. coli EOS 6 (11%), LOS 3 (10%)
Group B Streptococcus EOS 2 (4%), LOS 1 (3%)
Sigaúque et al. [21] Bacteremia rural, hospital recruitment 154 isolates: 16% blood cultures positive
Mozambique 2001-2006 <15 yrs S. aureus 60 (39%)
Group B Streptococcus 31 (20%)
E. coli 9 (6%)
S. pneumoniae 7 (5%)
Nielsen et al. [17] Bacteremia rural, hospital recruitment 23 isolates:
Ghana 2007-2009 <5 yrs S. aureus 6 (26%)
Klebsiella spp. 6 (26%)
Streptococcus spp. 3 (13%)
E. coli 3 (13%)
Non-tyhoid Salmonella 2 (9%)
Gray et al. [29] Group B
streptococcus
urban, hospital recruitment 290 isolates: 12% blood cultures positive
Malawi 2004-2005 <90 days Group B Streptococcus 48 (17%)
Talbert et al. [24] Neonatal sepsis rural, hospital recruitment 474 isolates: 9% blood cultures positive (25 infants had 2
bacterial species isolated)
Kenya 2001-2009 <60 days Klebsiella spp. 57 (13%)
S. aureus 55 (12%)
Acinetobacter spp. 48 (11%)
E. coli 41 (9%)
Group B Streptococcus 32 (7%)
86 isolates from CSF samples : 4% CSF cultures positive
S. pneumoniae 17 (20%)
Group B Streptococcus 16 (19%)
Salmonella spp. 10 (12%)
Ojukwu et al. [18] Neonatal sepsis urban, hospital recruitment 33 isolates: 24% blood cultures positive
Nigeria 2002-2003 0-28 days S. aureus 15 (45%)
E. coli 6 (18%)
Klebsiella spp. 3 (9%)
Group B Streptococcus 1 (3%)
Mugalu et al. [15] Neonatal sepsis urban, hospital recruitment 110 isolates: 37% blood or CSF cultures positive
Uganda 2002 used WHO
guidelines
S. aureus 69 (63%)
E. coli 17 (15%)
Group B Streptococcus 7 (6%)
Shitaye et al. [19] Neonatal sepsis urban, hospital recruitment 135 isolates: 45% blood cultures positive
Ethiopia 2006-2007 0-28 days Klebsiella spp. 53 (39%)
S. aureus 30 (22%)
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Table 2 Neonatal infections in developing countries (2000-May 2014) (Continued)
Coagulase-negative
Staphylococcus
10 (7%)
Mhada et al. Neonatal sepsis urban, hospital recruitment 52 early onset (EOS) isolates†: 22 late onset (LOS) isolates:
22.4% blood cultures positive
Tanzania 2009-2010 0-28 days S. aureus EOS 15 (29%), LOS 12 (55%)
Klebsiella spp. EOS 17 (33%), LOS 5 (23%)
E. coli EOS 10 (19%), LOS 4 (18%)
Staphylococcus epidermidis EOS 6 (12%), LOS 0 (0%)
Group B Streptococcus EOS 1 (2%), LOS 0 (0%)
Kiwanuka et al. [13] Neonatal sepsis urban, hospital recruitment 19 early onset (EOS) isolates†: 7 late onset (LOS) isolates:
33% blood cultures
Uganda 2010 <1 month S. aureus EOS 13 (68%), LOS 3 (43%)
E. coli EOS 3 (16%), LOS 1 (14%)
Klebsiella spp. EOS 1 (5%), LOS 1 (14%)
Group B Streptococcus EOS 1 (5%), LOS 0 (0%)
SE Asia
Stoesser et al. [22] Bacteremia urban, hospital recruitment 65 isolates:
Cambodia 2007-2011 <16 yrs Klebsiella spp. 14 (22%)
S. aureus 9 (14%)
Enterobacter spp. 4 (6%)
E. coli 3 (5%)
Streptococcus pyogenes 3 (5%)
Kruse et al. [30] Neonatal sepsis urban, hospital recruitment 399 isolates: 17% blood cultures positive
Vietnam 2009-2010 <28 days Klebsiella spp. 78 (20%)
Acinetobacter spp. 58 (15%)
E. coli 21 (5%)
Enterobacter spp. 16 (4%)
S. aureus 11 (3%)
Morganella spp. 8 (2%)
Pseudomonas spp. 6 (2%)
Coagulase-negative
Staphylococcus
175 (44%)
India subcontinent
Mir et al. [28] Omphalitis with
sepsis
urban, community
recruitment
432 isolates: 64% umbilical cord cultures positive
Pakistan 2004-2007 neonates
(<1 month)
S. aureus 225 (52%)‡
Streptococcus pyogenes 78 (18%)‡
Group B Streptococcus 43 (10%)‡
Jain et al. [26] Neonatal sepsis urban, hospital recruitment 350 isolates: 48% blood cultures positive for bacteria
India 2001-2002 Not defined Klebsiella spp. 86 (25%)‡
Enterobacter spp. 80 (23%)‡
E. coli 49 (14%)‡
Sundaram et al. [23] Neonatal sepsis urban, hospital recruitment 527 early onset (EOS) isolates§: 364 late onset (LOS) isolates:
India 1995–1998, 2001-
2006
Not defined S. aureus EOS 108 (20%), LOS 112
(31%)
K. pneumoniae EOS 62 (12%), LOS 49 (14%)
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Table 2 Neonatal infections in developing countries (2000-May 2014) (Continued)
Non-fermenting gram
negative bacilli
EOS 161 (30%), LOS 60 (17%)
E. coli EOS 48 (9%), LOS 40 (11%)
Zakariya et al. [25] Neonatal sepsis urban, hospital recruitment 50 isolates: 42% blood cultures positive
India 2004-2006 <= 30 days K. pneumoniae 33 (66%)
Coagulase-negative
Staphylococcus
6 (12%)
Group B Streptococcus 1 (2%)
Muhammad et al. [16] Neonatal sepsis urban, hospital recruitment 130 isolates:
Pakistan 2009-2010 <28 days S. aureus 35 (27%)
E. coli 30 (23%)
Staphylococcus epidermidis 17 (13%)
Acinetobacter spp. 17 (13%)
Klebsiella spp. 13 (10%)
Streptococcus species only found in early onset sepsis (first week)
Klebseilla species only found in late onset sepsis (after first week
to 28 days)
Darmstadt et al. [27] Neonatal sepsis rural, community recruitment 29 isolates: 6% blood cultures positive
Bangladesh 2004-2006 <28 days S. aureus 10 (34%)
S. pneumoniae 3 (10%)
Group B Streptococcus 1 (3%)
Gyawali et al. [12] Neonatal sepsis urban, hospital recruitment 238 isolates: 15% blood cultures positive
Nepal 2009-2010 first 4 weeks of life S. aureus 94 (40%)
Klebsiella spp. 32 (14%)
Acinetobacter spp. 30 (13%)
Enterobacter spp. 27 (11%)
Pseudomonas spp. 21 (9%)
E. coli 16 (7%)
Shresta et al. [20] Neonatal sepsis urban, hospital recruitment 37 isolates: 32% blood cultures positive
Nepal, 2011-2012 not defined S. aureus 21 (57%)
K. pneumoniae 8 (22%)
P. aeruginosa 5 (13%)
Europe
Macharashvili et al. [14] Neonatal sepsis urban, hospital recruitment 126 isolates: 67% blood cultures positive
Georgia 2003-2004 8 weeks or younger K. pneumoniae 36 (29%)
Enterobacter cloacae 19 (15%)
S. aureus 15 (12%)
Group B Streptococcus 6 (5%)
*Percentages calculated when not reported in the article. Pathogens listed in order of relative percentages.
†Early onset sepsis (EOS) defined as 0–6 days.
‡Number of isolates calculated from percentages presented in article.
§Early onset sepsis (EOS) defined as <72 hours, late onset (LOS) defined as >72 hours.
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where the risk of neonatal death is the highest.
We observed a broad range of neonatal infection inci-
dence estimates. This heterogeneity has been previously
noted by other authors [33,34] and emphasizes the needfor routine surveillance across settings to accurately esti-
mate the incidence and monitor trends of neonatal bac-
terial infections.
We found that the most common pathogens were S.
aureus, Klebsiella spp., and E. coli which account for
Figure 2 Incidence and aetiology of neonatal sepsis/bacteremia for 1000 live births in developing countries. Sources; [18,23,27-29] The
figure shows point estimates, 95% confidence intervals, and aetiology of neonatal infections along with recruitment strategy and setting. Studies
represented in blue were conducted in urban areas. Studies represented in orange were conducted in rural areas. Studies represented by a
triangle used hospital recruitment. Studies represented by a circle used community recruitment. GBS (Group B streptococcus). *The Incidence
estimate was calculated from the number of isolates and births presented. †CI estimated from data presented in the article. ‡The two estimates
were taken from the same study. § Each case had both omphalitis and clinically defined sepsis.
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tion is in line with others reviews conducted in DCs
[34,35]. Care must be taken when interpreting these re-
sults, however, as differentiation of infections into
community-acquired or hospital-acquired during the
neonatal period can be difficult in DCs [36]. As a result,
a small number of nosocomial infections may be in-
cluded in our findings, thus influencing the pathogen
distribution. Five studies were included in our analysis
which reported coagulase-negative Staphylococci as re-
sponsible for a significant proportion of neonatal infec-
tion, however positive blood cultures for this pathogen
may commonly be due to sample contamination.
The relative importance of the most common patho-
gens differs according to disease onset (early vs. late),
however this distinction was not detailed in the majority
of the studies. Early onset infections are generally attrib-
uted to pathogens transmitted from the vaginal or rectal
flora of the mother to the child, while late onset infec-
tions are attributed to bacteria acquired from the infant’s
surroundings (hospitals or community) with S. aureus
and Klebsiella species more frequently implicated in
hospital infections [37]. Infection control measures de-
signed to prevent the acquisition of bacteria from the
environment do not affect pathogens that are acquired
at birth. Therefore, distinguishing maternal from envir-
onmental infection sources would allow for improved
implementation of preventive strategies in these settings.Our results show that since 2000 few studies with reli-
able data focused on resistance patterns. In addition, the
number of isolates per study was generally very small:
three-quarters of the 12 studies reporting resistance
rates reported results based on fewer than than 30 iso-
lates. The WHO recommends ampicillin and gentamicin
as first-line treatment of neonatal sepsis unless there is
infection of the skin or umbilicus (possible S. aureus),
when cloxacillin is substituted for ampicillin. Our review
shows that resistance to ampicillin was high. Data on
gentamicin were heterogeneous and no clear conclusion
could be drawn. However, the findings of our review are
consistent with others studies [35] and confirm a trend
of growing resistance to this drug combination.
Data on resistance to third generation cephalosporins
were heterogeneous except among Klebsiella spp. for
which notable resistance rates were reported [25,26].
Moreover, only two studies reported testing for extended
spectrum beta-lactamase (ESBL) despite the fact that
ESBL have been reported worldwide. Medication re-
quired to treat ESBL-producing Enterobacteriaceae is
expensive and unaffordable for the majority of the popu-
lation in these settings making these bacteria difficult to
treat. It is therefore of the utmost importance to make
reliable data available to guide strategies devoted to lim-
iting the spread of ESBL pathogens in DCs.
Importantly, no conclusions can be drawn regarding
methicillin resistant S. aureus (MRSA), despite the fact
Table 3 Antibiotic resistance of bacteria isolated from invasive neonatal infections in developing countries (2000-May 2014)
Study, year Location, setting Pathogen Resistant% (95% CI)
Penicillin/ampicillin Gentamicin 3rd generation cephalosporins % ESBL*
Mugalu et al. [15] Uganda, urban 17 E. coli†, ‡ 100§ 29 (7–51) 6 (0–17) –
2002 7 Group B Streptococcus† 14 (0–40) 57 (20–94) – NA
Gray et al. [29] Malawi, urban 57 Group B Streptococcus† 0§ – 0§ NA
2004-2005
Shitaye et al. [19] Ethiopia, urban 30 S. aureus 67% (50–84) resistance to meticillin NA
2006-2007
Talbert et al. [24] Kenya, rural 48 Acinetobacter spp.†, || 56 (42–70) 27 (14–39) 35 (22–48) –
2001-2009 49 K. pneumoniae† 96 (91–100) 49 (35–63) 43 (29–57) –
39 S. pyogenes† 0§ – – –
41 E. coli† 78 (65–91) 10 (1–19) 17 (5–29) –
55 S. aureus† 0% resistance to meticillin§ NA
Mhada et al. Tanzania, urban 22 Klebsiella spp. || 100§ 77 (57–90) 18 (7–39) –
2009-2010 41 E. coli 93 (69–99) 43 (21-67 14 (4–40) –
Kruse et al. [30] Vietnam, urban 78 Klebsiella spp. †,|| 100§ 85 (75–91) 86 (76–92), 71 (60–79) ¶ –
2009-2010 58 Acinetobacter spp. †,|| 85 (73–92) 50 (38–62) 82 (71–80), 71 (58–81) ¶ –
21 E. coli† 86 (65–95) 57 (37–76) 58 (37–76), 42 (24–63) ¶ –
16 Enterobacter spp. †,|| 93 (72–99) 62 (39–82) 62 (39–82), 50 (28–72) ¶ –
6 Pseudomonas spp. †,|| 100§ 48 (19–81) 83 (44–97) ,33 (10–70) ¶ –
11 S. Aureus † 55% (28–79) resistance to meticillin
Jain et al. [26] India, urban 86 Klebsiella spp. || 100§ 89 (82–96) 63 (53–73), 49 (38–60) ¶ 87 (80–94)
2001-2002 80 Enterobacter spp. || 100§ 93 (87–99) 64 (53–75), 54 (43–65) ¶ 73 (63–83)
49 E. coli 96 (91–100) 90 (72–98) 65 (52–78), 41 (27–55) ¶ 65 (52–78)
Zakariya et al. [25] India, urban 33 K. pneumoniae† – 100§ 97(85–99), 97(85–99) ¶ 32 (20–50)
2004-2006
Mir et al. [28] Pakistan, urban 52 Pseudomonas spp. †,|| – 0§ – –
2004-2007 12 Klebsiella spp†,|| – 8 (0–23) 8 (0–23) –
9 E. coli† – 0§ 11 (0–31) –
304 S. aureus† 4% (2–6) resistance to meticillin
Gyawali et al. [12] Nepal, urban 82 Enterobacteriacea ? 94 (87–97) 70 (59–78) 83 (73–90), 79 (69–87), 87 (78–92) ¶ –
2009-2010 21 Pseudomonas spp. || – 37 (21–59) 47 (28–68), 71 (50–86), 67 (45–82) ¶ –
30 Acinetobacer spp. || – 56 (39–73) 53 (36–70), 65 (46–78), 73 (56–86) ¶ –
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Table 3 Antibiotic resistance of bacteria isolated from invasive neonatal infections in developing countries (2000-May 2014) (Continued)
Shresta et al. [20] Nepal, urban 8 K. pneumoniae 38 (14–69) 0§ – –
2011-2012
Macharashvili et al. [14] Georgia, urban 45 Klebsiella spp. †,‡, || 98 (94–100) 11 (2–20) 16 (5–27), 18 (7–29) ¶ –
2003-2004 11 E. coli†,‡ 55 (26–84) 18 (0–41) 9 (0–26), 9 (0–26) ¶ –
15 S. aureus 40% (15–65) resistance to meticillin
*Extended-spectrum beta-lactamase.
†Results were presented for sensitivity, resistance calculated as 100 minus% sensitive.
‡Penicillin results based on amoxicillin.
§Calculation of a CI was impossible.
||Pathogens marked spp. means no further characterization was presented.
¶Multiple 3GCs were tested.
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Huynh et al. BMC Infectious Diseases  (2015) 15:127 Page 11 of 13that this pathogen may be the first cause of neonatal
infection. Furthermore, only one of the six studies in our
review describing MRSA infection was conducted in a
community setting. Community-associated MRSA (CA-
MRSA) has emerged in the developed world and repre-
sents a growing problem. Data on CA-MRSA are scarce
in DCs, despite the existence of risk factors associated
with drug resistance in the community, such as over-
the-counter antibiotics use, overcrowding, and poor hy-
giene are highly prevalent [38].
Our review highlights the scarcity and heterogeneity of
the available data on both the incidence of invasive bac-
terial infection and resistance patterns. While these find-
ings may reflect true differences in the burden of
neonatal infection and among resistance patterns, they
may also be explained by major differences in data-
collection methods. The currently available data are thus
insufficient to draw a true picture of the burden of inva-
sive bacterial infections and resistance. Furthermore, the
reported infection rates are likely to underestimate the
true incidence. Three-quarters of the studies reviewed
took place in urban settings with recruitment at large or
teaching hospitals. In DCs, the majority of families do
not seek care in hospitals, particularly in rural areas, be-
cause of resource constraints, distances to their homes,
or differences in health care seeking behaviours [39].
This is particularly true for early onset neonatal sepsis in
the context of home deliveries. Along with underesti-
mating the incidence, these factors undoubtedly play a
role in the low detection rates of Group B Streptococcus
in DCs as these infections generally occur in the few
hours after delivery. These results are contrary to those
from developed countries where Group B Streptococcus
is the major cause of neonatal sepsis [40,41].
The observed heterogeneity among incidence rates may
also be explained by the difficulty of estimating these rates.
Such estimates require population surveillance systems,
which are expensive and time-consuming and are often
lacking in DCs. Indeed, less than one-fifth of the studies
reviewed were based on active surveillance. An additional
factor is the difficulty to confirm diagnosis with blood cul-
ture. A positive blood culture requires adequate blood vol-
ume drawn in strict aseptic conditions by skilled staff at
the right moment along with access to appropriate labora-
tory equipment and techniques accessible almost exclu-
sively in large or teaching hospitals in DCs [42,43].
Furthermore, only two studies performed two blood cul-
tures despite an increased chance of pathogen isolation.
The proportion of antibiotic usage prior to blood culture
performed at the hospital was also high among studies
reporting. Thus, a single negative blood culture cannot
completely rule out an infection and a substantial propor-
tion of non-microbiologically confirmed sepsis cases po-
tentially represents false-negatives [44].Assessment of antibiotic resistance was often based on
few isolates collected over several years, which is clearly
insufficient to describe trends in bacterial resistance to
antibiotics. Almost one-third of the studies reviewed did
not refer to any guidelines for interpretation of antibiotic
susceptibility, which may call into question the reliability
of their results. Given the heterogeneity in antimicrobial
susceptibility references, comparisons between studies
are difficult. Of note, almost half of the studies reviewed
were conducted in Africa. The observed lack of studies
in Southeast Asia is alarming as the population in this
area is greater than in Africa.
The relative paucity of reports on antibiotic resistance
collected after 2008 is of particular concern in a context
of rapidly evolving resistance profiles and emerging anti-
biotic resistance mechanisms. Real-time data are re-
quired to provide an accurate understanding of drug
sensitivity and resistance patterns [5]. Although a poten-
tial explanation may be that recent data collected is less
likely to be published, the period of time that has
elapsed since 2007 is largely sufficient to reveal a decline
in publications.
A recent study published following our last search date
deserves to be mentioned. This study included 8889
infants under 2 months brought to health facilities for
illness in 6 DCs. Blood culture was performed for more
than 10% of these children and antibiotic susceptibility
testing was conducted on isolated bacteria. Pathogen
distributions and antibiotic sensitivity patterns were
similar to our findings [45].
In its first report on global antimicrobial resistance,
with data from 114 countries, the WHO found that re-
sistance to seven common bacteria has reached alarming
levels in all regions of the world [6]. It also highlights
that many gaps exist in documentation of pathogens of
major public health importance. Our analysis is in line
with the WHO’s conclusion on the need for methodo-
logical standards to investigate these issues. The WHO
report also draws attention to the fact that resistance
may be overestimated in the general population as most
reported samples were collected in large hospitals, con-
sistent with our observation that data from the commu-
nity are lacking. Finally, the WHO calls for actions to
strengthen and coordinate collaboration to address these
knowledge gaps.
Effective surveillance systems or research programs
devoted to anti-infective resistance in infectious diseases
such as tuberculosis, malaria, or HIV have been imple-
mented over the past few years with the active support
of various stakeholders (donors agencies, governments,
research institutes). These systems have been able to
provide reliable data allowing for the promotion of glo-
bal action. International alliances to contain antibiotic
resistance in DCs exist and have called for several
Huynh et al. BMC Infectious Diseases  (2015) 15:127 Page 12 of 13actions including global research and surveillance, public
health advocacy, and consumer and practitioner educa-
tion. However, current research projects are often based
in large or teaching hospitals, and drug resistance pat-
terns and trends in antibiotic use are based on data from
these hospitals. It is therefore imperative to accurately
assess the burden of antibiotic-resistant infections in
DCs, particularly among children as they bear the high-
est burden.
Conclusion
Despite the recent global awareness of bacterial resist-
ance issues and indications of the growing antibiotic re-
sistance in DCs, epidemiological evidence remains limited
and available data are not sufficient to draw a true, recent,
and accurate picture of antibiotic resistance in DCs among
neonates and particularly in the community.
Neonatal bacterial diseases are a major cause of death
in these countries, and the risk of bacterial resistance
emergence and dissemination is exacerbated by poor
antibiotic control and precarious living conditions. With-
out data to evaluate the burden of antibiotic resistance in
this population, the public health problem will undoubt-
edly remain underserved. Future research should be able
to collect quality, standardized epidemiological data along
with a reliable bacteriological diagnosis at the community
level in order to allow for adapted public health measures
necessary to combat antibiotic resistance.
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